NRIP1 and acute myeloid leukemia: Knockdown of NRIP1 in 3q-rearranged cell lines reduced the proliferation and viability of these AML cells and was also able to increase their sensitivity towards treatment with all-trans-retinoic acid (ATRA),90 making NRIP1 a potential therapeutic target in EVI1high AML cases.